ClinicalTrials.gg

Program

M701

A development code. Also written as “M701 pleural infusion”.

Its studies are mostly in Pleural Effusion, Malignant, led by Wuhan YZY Biopharma.

Furthest: phase 2, since Sep 14, 20221 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wuhan YZY Biopharma11 open or runningphase 2since Sep 14, 2022Sep 14, 2022none ahead
  • Named in sino biopharmaceutical’s own pipeline as M701, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2022First study: phase 2 study in Pleural Effusion, MalignantFirst studyNCT05543330 · 116 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05543330Pleural Effusion, Malignant · China2RecruitingSep 15, 2026116

How it is read

Names in the registry

  • “M701 pleural infusion”, 1 entry

Codes read as this program: M701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.